1.28

36.46% 0.342

Xilio Therapeutics Inc (XLO)

Overview News Price History Financials Discussions Forecast

Xilio Therapeutics Inc stock is traded at $1.28, with a volume of 6.78M. It is up +36.46% in the last 24 hours and up +36.00% over the past month. Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).

Previous Close:

$0.938

Open:

$1.06

24h Volume:

6.78M

Relative Volume:

17.42

Market Cap:

$56.27M

Revenue:

Net Income/Loss:

$-81.22M

P/E Ratio:

-0.4169

EPS:

-3.07

Net Cash Flow:

$-74.41M

1W Performance:

+32.12%

1M Performance:

+36.00%

6M Performance:

+34.23%

1Y Performance:

+155.80%

1-Day Range:

$0.8364

$1.28

1-Week Range:

$0.8235

$1.28

52-Week Range:

$0.5001

$1.93

Xilio Therapeutics Inc Stock (XLO) Company Profile

Name

Xilio Therapeutics Inc

Sector

Healthcare (1176)

Industry

Biotechnology (673)

Phone

617-833-1027

Address

828 WINTER STREET, WALTHAM

Employee

Twitter

Next Earnings Date

2024-11-09

Latest SEC Filings

XLO's Discussions on Twitter

Compare XLO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
XLO Xilio Therapeutics Inc	1.28	56.27M	0	-81.22M	-74.41M	-2.96
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Xilio Therapeutics Inc Stock (XLO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-21-22	Initiated	Chardan Capital Markets	Buy
Jan-10-22	Initiated	H.C. Wainwright	Buy
Nov-16-21	Initiated	Cowen	Outperform
Nov-16-21	Initiated	Guggenheim	Buy
Nov-16-21	Initiated	Morgan Stanley	Overweight
Nov-16-21	Initiated	Raymond James	Outperform

View All

Xilio Therapeutics Inc Stock (XLO) Latest News

Dec 21, 2024

Xilio Therapeutics Enters into Additional Private Placement with Gilead; Issues Securities at $25 Million Aggregate Investment - Defense World

Dec 21, 2024

Dec 19, 2024

Gilead Sciences acquires $1.83 million in Xilio Therapeutics stock By Investing.com - Investing.com Canada

Dec 19, 2024

Gilead Sciences acquires $1.83 million in Xilio Therapeutics stock - Investing.com India

Dec 19, 2024

Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated - The Bakersfield Californian

Dec 19, 2024

Xilio Therapeutics to Present Initial Phase 2 Data for - GlobeNewswire

Dec 19, 2024

Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI - Yahoo Finance

Dec 19, 2024

Dec 16, 2024

Xilio Therapeutics Hires Caroline Hensley as Chief Legal Officer - Bloomberg Law

Dec 16, 2024

Biotech Biz Xilio Therapeutics Appoints Chief Legal Officer - Law360

Dec 16, 2024

Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer - The Bakersfield Californian

Dec 16, 2024

Xilio Therapeutics, Inc. Appoints Caroline Hensley as chief legal officer - Marketscreener.com

Dec 16, 2024

Dec 10, 2024

After Golden Cross, Xilio Therapeutics, Inc. (XLO)'s Technical Outlook is Bright - MSN

Dec 10, 2024

Dec 06, 2024

Here's Why We're Not Too Worried About Xilio Therapeutics' (NASDAQ:XLO) Cash Burn Situation - Yahoo Finance

Dec 06, 2024

Dec 03, 2024

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Dec 03, 2024

Nov 11, 2024

Raymond James Cuts Xilio Therapeutics (NASDAQ:XLO) Price Target to $4.00 - Defense World

Nov 11, 2024

Nov 08, 2024

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results - citybiz

Nov 07, 2024

Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors - GlobeNewswire

Nov 07, 2024

Xilio's Cancer Drug Shows Promise: Liver Metastasis Resolution in Clinical Trial | XLO Stock News - StockTitan

Nov 07, 2024

Oct 30, 2024

Xilio Therapeutics to Present Initial Phase 1C Dose - GlobeNewswire

Oct 30, 2024

Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - GlobeNewswire Inc.

Oct 30, 2024

Oct 25, 2024

Companies Like Xilio Therapeutics (NASDAQ:XLO) Are In A Position To Invest In Growth - Simply Wall St

Oct 25, 2024

Oct 04, 2024

Xilio Therapeutics Announces Upcoming Poster Presentation - GlobeNewswire

Oct 04, 2024

Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of - The Bakersfield Californian

Oct 04, 2024

Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - StockTitan

Oct 04, 2024

Sep 23, 2024

XOS stock touches 52-week low at $4.62 amid market challenges - Investing.com

Sep 23, 2024

XBP stock plunges to 52-week low at $1.05 amid market challenges - Investing.com

Sep 23, 2024

XPEV: Riding the Market Waves of Growth and Decline in 2023 - The InvestChronicle

Sep 23, 2024